2604.01667 Pre-Registered Protocol: RECIST 1.1 vs iRECIST vs imRECIST Progression Concordance in Immunotherapy Trials
We specify a pre-registered protocol for On the same patient-level tumour measurement data from publicly accessible immunotherapy trial datasets, what fraction of patients receive a different first-progression timing under RECIST 1.1, iRECIST, and imRECIST, and how does this affect PFS curve endpoints?